|
|
|
Substance Name: Regorafenib [USAN:INN]
RN: 755037-03-7
UNII: 24T2A1DOYB
InChIKey: FNHKPVJBJVTLMP-UHFFFAOYSA-N
Notes
- Has antineoplastic activity.
NCI: An orally bioavailable small molecule with potential antiangiogenic and antineoplastic activities. Regorafenib binds to and inhibits vascular endothelial growth factor receptors (VEGFRs) 2 and 3, and Ret, Kit, PDGFR and Raf kinases, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation. VEGFRs are receptor tyrosine kinases that play important roles in tumor angiogenesis; the receptor tyrosine kinases RET, KIT, and PDGFR, and the serine/threonine-specific Raf kinase are involved in tumor cell signaling. (NCI Thesaurus) - Has both antiangiogenic and antineoplastic activities.
Molecular Formula
- C21-H15-Cl-F4-N4-O3
Molecular Weight
- 482.8195
Classification Code
- Antineoplastic Agents
* denotes mobile formatted website
Links to Resources
NLM Resources (File Locators)
Other Resources (Internet Locators)
Search for this InChIKey on the Web
Names and Synonyms
Name of Substance
- Regorafenib [USAN:INN]
Synonyms
- 4-(4-(((4-Chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-n-methylpyridine-2-carboxamide
- BAY 73-4506
- BAY-73-4506
- BAY73-4506
- Regorafenib
- Regorafenibum
- Stivarga
- UNII-24T2A1DOYB
Systematic Name
- 4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl}amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide
Registry Numbers
CAS Registry Number
- 755037-03-7
FDA UNII
- 24T2A1DOYB
System Generated Number
- 0755037037